Qualia Life Sciences announcing groundbreaking clinical results for their new supplement, Qualia NAD+. In two 28-day double-blind, placebo-controlled studies, Qualia NAD+ demonstrated a remarkable 67% increase in NAD+ levels – results that surpass previous benchmarks in NAD+ supplementation.
For those unfamiliar, NAD+ (nicotinamide adenine dinucleotide) is a critical molecule found in every cell of the human body, playing an essential role in energy metabolism, DNA repair, and cellular health. By the time most individuals hit 40, their NAD+ levels plummet to nearly half of what they were at 20, contributing to faster aging and reduced vitality.
Historically, elevating NAD+ levels has been a challenge. Direct supplementation struggles with bioavailability, and while IV treatments exist, they remain costly and inaccessible for many consumers. Qualia’s innovative approach tackles these barriers by combining three distinct NAD+ precursors and key co-factors to optimize the body’s ability to naturally produce NAD+.
James Schmachtenberger, CEO of Qualia Life Sciences, expressed his excitement:
“We sought to support optimal conditions for the body to generate more of its own NAD+. The clinical results reflect our nuanced approach, and we couldn’t be happier with the outcomes.”
This development is a game-changer for retailers of natural products and supplements. With ever-growing consumer interest in anti-aging solutions and cellular health, Qualia NAD+ is poised to be a strong contender in the premium supplement market.
Stay tuned for more updates on cutting-edge products reshaping the natural health industry!
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
